Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
11 pending office actions • 6 art units • 11 examiners • 0 of 11 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
Glaxosmithkline Intellectual Property Development Limited Gsk Medicines Research Centre currently has 1 pending office action. This action defines the current prosecution landscape for the company. The portfolio is handled by 1 distinct examiner, which indicates a centralized point of interaction with the patent office for the current pending matter. For a practitioner, the focus is entirely on the pending office action and the specific examiner assigned to it. This streamlined structure allows for a highly focused approach to the company's intellectual property goals.
The data shows 0 distinct art units associated with the pending action. This figure of 0 might be due to the current administrative status of the application or its specific classification within the patent office. KEOGH, MATTHEW R is the busiest examiner for the company, being responsible for the pending office action currently on record. This examiner represents the group of active examiners for the company. The lack of multiple art units or examiners simplifies the administrative burden of managing this filing.
The fact that a distinct examiner is managing the pending office action means that the outcome of this interaction is critical for the portfolio. KEOGH, MATTHEW R holds the 1 pending action, making this individual the primary focus for any upcoming interviews or responses. The concentration of the pending office action under the examiner simplifies the communication strategy, as there are no competing examiner styles to navigate. With only 1 pending office action, the practitioner can dedicate full attention to the specific requirements and feedback from this single examiner.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (9%) |
| §103 only | 1 (9%) |
| §112 only | 2 (18%) |
| Double-patenting only | 1 (9%) |
| Double-patenting + other | 3 (27%) |
| Multi-statute (no §101) | 3 (27%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VAJDA, KRISTIN ANN | 1 | 84.0% | +10.9% |
| REYNOLDS, FRED H | 1 | 33.0% | +39.2% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
| SHIM, DAVID M. | 1 | 58.3% | +58.3% |
| NATARAJAN, MEERA | 1 | 62.5% | +18.0% |
| RZECZYCKI, PHILLIP MATTHEW | 1 | 64.8% | +37.0% |
| WEIDNER, ADAM M | 1 | 63.5% | +33.8% |
| TCHERKASSKAYA, OLGA V | 1 | 55.4% | +46.2% |
| JOHNSON, TIRONE DEREK | 1 | 0.0% | +0.0% |
| BELYAVSKYI, MICHAIL A | 1 | 64.2% | +27.6% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18943115 | 5,6,7,7a-Tetrahydrocyclopenta[f]pyrido[1,2-h][1,7] naphthyridin-11(4bH)-one Compounds and Methods of use Use (as amended) | VAJDA, KRISTIN ANN | — |
| 18739860 | PI4KIIIBETA INHIBITORS | WILLIS, DOUGLAS M | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18569648 | Pharmaceutical Compound | RZECZYCKI, PHILLIP MATTHEW | 53d |
| 18562868 | Combination Therapies for Treating Cancer | WEIDNER, ADAM M | — |
| 18262938 | ORAL SOLID DOSE FORMULATIONS | TCHERKASSKAYA, OLGA V | — |
| 18258588 | INTERLEUKIN 5 BINDING PROTEIN DOSAGE REGIMEN | JOHNSON, TIRONE DEREK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18569648 | Pharmaceutical Compound | RZECZYCKI, PHILLIP MATTHEW | 53d |
| 18943115 | 5,6,7,7a-Tetrahydrocyclopenta[f]pyrido[1,2-h][1,7] naphthyridin-11(4bH)-one Compounds and Methods of use Use (as amended) | VAJDA, KRISTIN ANN | — |
| 18728991 | GEPOTIDACIN AND VANCOMYCIN FOR USE IN THE TREATMENT OF AN INFECTION CAUSED BY STAPHYLOCOCCUS SAPROPHYTICUS | REYNOLDS, FRED H | — |
| 18739860 | PI4KIIIBETA INHIBITORS | WILLIS, DOUGLAS M | — |
| 18646178 | COMPOUNDS | SHIM, DAVID M. | — |
| 18697515 | Combination Therapies for Treating Cancer | NATARAJAN, MEERA | — |
| 18562868 | Combination Therapies for Treating Cancer | WEIDNER, ADAM M | — |
| 18262938 | ORAL SOLID DOSE FORMULATIONS | TCHERKASSKAYA, OLGA V | — |
| Art Unit | Apps |
|---|---|
| 1629 | 2 |
| 1643 | 1 |
| 1625 | 1 |
| 1615 | 1 |
| 1675 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18943115 | 5,6,7,7a-Tetrahydrocyclopenta[f]pyrido[1,2-h][1,7] naphthyridin-11(4bH)-one Compounds and Methods of use Use (as amended) | VAJDA, KRISTIN ANN | — | DP | Non-Final OA | — | Pending | Nov 11, 2024 |
| 18728991 | GEPOTIDACIN AND VANCOMYCIN FOR USE IN THE TREATMENT OF AN INFECTION CAUSED BY STAPHYLOCOCCUS SAPROPHYTICUS | REYNOLDS, FRED H | — | §102§103§112DP | Non-Final OA | — | Pending | Jul 15, 2024 |
| 18739860 | PI4KIIIBETA INHIBITORS | WILLIS, DOUGLAS M | — | §112Other | Non-Final OA | — | Pending | Jun 11, 2024 |
| 18646178 | COMPOUNDS | SHIM, DAVID M. | 1629 | §103Other | Non-Final OA | — | Pending | Apr 25, 2024 |
| 18697515 | Combination Therapies for Treating Cancer | NATARAJAN, MEERA | 1643 | §102§103DP | Non-Final OA | — | Pending | Apr 01, 2024 |
| 18569648 | Pharmaceutical Compound | RZECZYCKI, PHILLIP MATTHEW | 1625 | §101§112 | Non-Final OA | 53d | Pending | Dec 13, 2023 |
| 18562868 | Combination Therapies for Treating Cancer | WEIDNER, ADAM M | — | §102§103 | Non-Final OA | — | Pending | Nov 21, 2023 |
| 18262938 | ORAL SOLID DOSE FORMULATIONS | TCHERKASSKAYA, OLGA V | 1615 | §103§112 | Final Rejection | — | Pending | Jul 26, 2023 |
| 18258588 | INTERLEUKIN 5 BINDING PROTEIN DOSAGE REGIMEN | JOHNSON, TIRONE DEREK | 1675 | §102§103§112Other | Non-Final OA | — | Pending | Jun 21, 2023 |
| 18098792 | ANTIGEN BINDING PROTEINS | BELYAVSKYI, MICHAIL A | 1644 | §112DP | Final Rejection | — | Pending | Jan 19, 2023 |
| 17412070 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | SCHMITT, MICHAEL J | 1629 | §112Other | Final Rejection | 29d | Pending | Aug 25, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial